Equities Analysts Set Expectations for Sarepta Therapeutics, Inc.’s FY2026 Earnings (NASDAQ:SRPT)

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) – Equities research analysts at Zacks Research cut their FY2026 EPS estimates for Sarepta Therapeutics in a report released on Tuesday, April 23rd. Zacks Research analyst S. Ganoria now anticipates that the biotechnology company will earn $10.13 per share for the year, down from their prior estimate of $11.48. The consensus estimate for Sarepta Therapeutics’ current full-year earnings is $2.13 per share.

Other analysts have also recently issued research reports about the stock. TheStreet raised shares of Sarepta Therapeutics from a “d” rating to a “c-” rating in a research report on Monday, March 4th. Barclays increased their price objective on shares of Sarepta Therapeutics from $141.00 to $185.00 and gave the stock an “overweight” rating in a research report on Thursday, February 29th. Royal Bank of Canada increased their price objective on shares of Sarepta Therapeutics from $151.00 to $157.00 and gave the stock an “outperform” rating in a research report on Thursday, February 29th. Wedbush reissued an “outperform” rating and set a $224.00 price objective on shares of Sarepta Therapeutics in a research report on Thursday, February 29th. Finally, Needham & Company LLC cut their price objective on shares of Sarepta Therapeutics from $169.00 to $166.00 and set a “buy” rating on the stock in a research report on Thursday, February 29th. Four equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $158.38.

Sarepta Therapeutics Stock Performance

Shares of SRPT opened at $127.39 on Thursday. The company has a current ratio of 3.95, a quick ratio of 3.45 and a debt-to-equity ratio of 1.32. The stock has a market capitalization of $11.96 billion, a P/E ratio of -20.82 and a beta of 0.94. The firm’s fifty day simple moving average is $126.22 and its two-hundred day simple moving average is $110.43. Sarepta Therapeutics has a 12 month low of $55.25 and a 12 month high of $159.89.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings results on Wednesday, February 28th. The biotechnology company reported $0.47 EPS for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.50. The business had revenue of $396.80 million for the quarter, compared to analysts’ expectations of $387.18 million. Sarepta Therapeutics had a negative net margin of 43.11% and a negative return on equity of 18.97%. The business’s quarterly revenue was up 53.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($1.24) earnings per share.

Insider Buying and Selling at Sarepta Therapeutics

In other Sarepta Therapeutics news, Director Hans Lennart Rudolf Wigzell sold 15,000 shares of the stock in a transaction dated Friday, March 8th. The shares were sold at an average price of $123.25, for a total value of $1,848,750.00. Following the completion of the sale, the director now owns 22,840 shares in the company, valued at approximately $2,815,030. The transaction was disclosed in a document filed with the SEC, which is available at this link. In related news, Director Kathryn Jean Boor sold 761 shares of the firm’s stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $122.93, for a total value of $93,549.73. Following the completion of the transaction, the director now directly owns 7,516 shares of the company’s stock, valued at approximately $923,941.88. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Hans Lennart Rudolf Wigzell sold 15,000 shares of the firm’s stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $123.25, for a total transaction of $1,848,750.00. Following the completion of the transaction, the director now directly owns 22,840 shares of the company’s stock, valued at $2,815,030. The disclosure for this sale can be found here. In the last 90 days, insiders sold 22,096 shares of company stock worth $2,739,419. Insiders own 7.40% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of SRPT. Principal Securities Inc. bought a new position in Sarepta Therapeutics in the 4th quarter worth approximately $26,000. Mather Group LLC. bought a new stake in shares of Sarepta Therapeutics during the 1st quarter worth $28,000. Montag A & Associates Inc. bought a new stake in shares of Sarepta Therapeutics during the 3rd quarter worth $30,000. Cary Street Partners Investment Advisory LLC raised its position in Sarepta Therapeutics by 154.0% in the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 254 shares of the biotechnology company’s stock worth $31,000 after purchasing an additional 154 shares during the period. Finally, GAMMA Investing LLC raised its position in Sarepta Therapeutics by 37.0% in the 1st quarter. GAMMA Investing LLC now owns 322 shares of the biotechnology company’s stock worth $42,000 after purchasing an additional 87 shares during the period. 86.68% of the stock is owned by institutional investors.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.